Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
Holding REGN?
Track your performance easily
REGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$666.25 - $1,211.20
Previous CloseN/A
Volume208.99K
Average Volume (3M)869.44K
Market Cap
$76.18B
Enterprise Value$115.06B
Total Cash (Recent Filing)$1.04B
Total Debt (Recent Filing)$351.57M
Price to Earnings (P/E)17.2
Beta0.77
Next Earnings
Feb 04, 2025EPS Estimate
11.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)40.41
Shares Outstanding108,072,390
10 Day Avg. Volume909,680
30 Day Avg. Volume869,441
Standard Deviation0.09
R-Squared0.00319
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.50
Price to Cash Flow (P/CF)14.80
P/FCF Ratio18.20
Enterprise Value/Market Cap1.51
Enterprise Value/Revenue8.31
Enterprise Value/Gross Profit10.18
Enterprise Value/Ebitda20.91
Forecast
1Y Price Target
$1,026.70Price Target Upside50.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Regeneron News
PremiumMarket News
QQQ ETF News, 1/17/2025
PremiumMarket News
SPY ETF News, 1/16/2025
PremiumMarket News
VOO ETF News, 1/15/2025
PremiumMarket News
QQQ ETF News, 1/14/2025Bulls Say, Bears Say
Bulls Say
Market PositionEylea franchise leadership is maintained with a 44% category share, leading the space as the market continues to expand.
Product LaunchThe Dupixent COPD launch is off to a successful start with coverage secured from top commercial and Medicare payers.
Product PerformanceLibtayo has been successful for adjuvant cutaneous squamous cell carcinoma, indicating favorable treatment outcomes.
Bears Say
Financial PerformanceEYLEA HD sales were unfavorably impacted by wholesale inventory and could be further impacted by Amgen's EYLEA biosimilar launch.
Investor UncertaintyThe company's lack of detailed financial guidance on the situation adds uncertainty for investors.
Market CompetitionAmgen's Pavblu is gaining a strong foothold due to better economic value and availability, challenging Eylea's market position.
---
Ownership Overview
1.95% Insiders
33.40% Mutual Funds
0.37% Other Institutional Investors
38.98% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $666.25 and its highest was $1211.20 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $76.18B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Feb 04, 2025 which is in 16 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Oct 31, 2024. The company reported $12.46 earnings per share for the quarter, beating the consensus estimate of $11.695 by $0.765.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 11.21.
How many shares outstanding does Regeneron have?
Regeneron has 108,072,390 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $12.46 in its last earnings report, beating expectations of $11.695. Following the earnings report the stock price went down -9.167%.
Which hedge fund is a major shareholder of Regeneron?
Among the largest hedge funds holding Regeneron’s share is Dodge & Cox. It holds Regeneron’s shares valued at 2B.
---
Regeneron Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,026.70 (50.64% Upside)
$1,026.70 (50.64% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 56.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.64%
12-Months-Change
Fundamentals
Return on Equity
17.17%
Trailing 12-Months
Asset Growth
16.41%
Trailing 12-Months
Company Description
Regeneron
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
REGN Company Deck
---
REGN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook driven by strong revenue growth and successful product performances, particularly Dupixent and EYLEA HD. However, there are challenges due to market competition and pricing pressures. Overall, the sentiment is cautiously optimistic, with significant growth opportunities anticipated in 2025.Read More>---
REGN Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
REGN Stock 12 Month Forecast
Average Price Target
$1,026.70
▲(50.64% Upside)
Technical Analysis
Amgen
―
BioMarin Pharmaceutical
―
Gilead Sciences
―
Vertex Pharmaceuticals
―
Incyte
―
Biogen
―
Best Analysts Covering REGN
1 Year
1 Year Success Rate
29/42 ratings generated profit
1 Year Average Return
+17.81%
reiterated a buy rating last month
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 69.05% of your transactions generating a profit, with an average return of +17.81% per trade.
---